,36 The identified M2-like-differentiated macrophages have recently moved into the spotlight of immunotherapy: combined anti-GD2/CD47 therapy to activate Mφ resulted in highly promising anti-tumor activity, accompanied by recruitment of M1-like Mφ and reduced M2-like Mφ.28 The gene discussed is CD47; the disease is neoplasm.